23077-43-2Relevant articles and documents
METHODS OF TREATING CANCER
-
Paragraph 00206, (2020/06/10)
The present disclosure relates to methods of treating cancer in a patient using a combination of an inhibitor of an immune checkpoint protein and an indole compound or its phosphate derivative.
Novel indole derivative and medicine containing the same (by machine translation)
-
Paragraph 0168; 0170, (2018/06/30)
[A] formation of Amyloid fibrils can be compounds, including therapeutic or prophylactic agent for neurodegenerative disease Amyloid fibrils formation inhibitor compound and of. (I) or its pharmaceutically acceptable compound represented by the formula [a] or a salt or solvate thereof includes the, Amyloid fibrils formation inhibitor. [R1 And R2 Each independently is H, an alkyl group, a cyano group or the like; R3 And R4 Each independently is H, or an alkyl group; R3 And R4 The, joint may form a ring; Ar1 And Ar2 The substituted or unsubstituted heteroaryl group are independently substituted/unsubstituted aryl groups /; X and Y are each independently a single bond, - (=O) - C etc., Z is O or CH2 ; N is an integer of 1 - 3][Drawing] no (by machine translation)
N -[6-(4-Butanoyl-5-methyl-1 H -pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1 H -indole-3-carboxamide (SAR216471), a Novel Intravenous and Oral, Reversible, and Directly Acting P2Y12 Antagonist
Boldron, Christophe,Besse, Angélina,Bordes, Marie-Fran?oise,Tissandié, Stéphanie,Yvon, Xavier,Gau, Benjamin,Badorc, Alain,Rousseaux, Tristan,Barré, Guillaume,Meneyrol, Jér?me,Zech, Gernot,Nazare, Marc,Fossey, Valérie,Pflieger, Anne-Marie,Bonnet-Lignon, Sandrine,Millet, Laurence,Briot, Christophe,Dol, Frédérique,Hérault, Jean-Pascal,Savi, Pierre,Lassalle, Gilbert,Delesque, Nathalie,Herbert, Jean-Marc,Bono, Fran?oise
supporting information, p. 7293 - 7316 (2015/01/08)
In the search of a potential backup for clopidogrel, we have initiated a HTS campaign designed to identify novel reversible P2Y12 antagonists. Starting from a hit with low micromolar binding activity, we report here the main steps of the optimization process leading to the identification of the preclinical candidate SAR216471. It is a potent, highly selective, and reversible P2Y12 receptor antagonist and by far the most potent inhibitor of ADP-induced platelet aggregation among the P2Y12 antagonists described in the literature. SAR216471 displays potent in vivo antiplatelet and antithrombotic activities and has the potential to differentiate from other antiplatelet agents.
